Patricia LoRusso

5.2k total citations
66 papers, 2.0k citations indexed

About

Patricia LoRusso is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Patricia LoRusso has authored 66 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 27 papers in Molecular Biology and 17 papers in Cancer Research. Recurrent topics in Patricia LoRusso's work include Cancer Immunotherapy and Biomarkers (10 papers), HER2/EGFR in Cancer Research (8 papers) and Cancer, Hypoxia, and Metabolism (8 papers). Patricia LoRusso is often cited by papers focused on Cancer Immunotherapy and Biomarkers (10 papers), HER2/EGFR in Cancer Research (8 papers) and Cancer, Hypoxia, and Metabolism (8 papers). Patricia LoRusso collaborates with scholars based in United States, Japan and Spain. Patricia LoRusso's co-authors include Ian E. Krop, Shanu Modi, Kathy D. Miller, Hope S. Rugo, Gladys Rodriguez, Ellie Guardino, Lukas C. Amler, Sandhya Girish, Eric P. Winer and Denise A. Yardley and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Patricia LoRusso

62 papers receiving 2.0k citations

Peers

Countries citing papers authored by Patricia LoRusso

Since Specialization

Citations

This map shows the geographic impact of Patricia LoRusso's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patricia LoRusso with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patricia LoRusso more than expected).

Fields of papers citing papers by Patricia LoRusso

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patricia LoRusso. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patricia LoRusso. The network helps show where Patricia LoRusso may publish in the future.

Co-authorship network of co-authors of Patricia LoRusso

This figure shows the co-authorship network connecting the top 25 collaborators of Patricia LoRusso. A scholar is included among the top collaborators of Patricia LoRusso based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patricia LoRusso. Patricia LoRusso is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study 2025 ·British Journal of Cancer ·Timothy A. Yap, Patricia LoRusso, Rowan Miller, Rebecca Kristeleit, Amanda G. Paulovich, Stephen McMorn, Lenka Oplustil O’Connor, (unknown), Paola Marco‐Casanova, Eric T. Gangl, Bharat Patel, Mark J. O’Connor, Emma Dean, (unknown), Ruth Plummer	2
2	Phase I dose-escalation and pharmacodynamic study of STING agonist E7766 in advanced solid tumors 2025 ·Journal for ImmunoTherapy of Cancer ·Jason J. Luke, David J. Pinato, Dejan Juric, Patricia LoRusso, Peter J. Hosein, Anupam M. Desai, Robert I. Haddad, Maria J. de Miguel, Andrés Cervantes, (unknown), Aurélien Marabelle, Yan Zhang, (unknown), (unknown), Stéphane Champiat	11
3	1000MO A phase I/II, open-label study of the novel checkpoint IGSF8 inhibitor GV20-0251 in patients with advanced solid tumors 2024 ·Annals of Oncology ·(unknown), (unknown), (unknown), Patricia LoRusso, Janice M. Mehnert, Alexander I. Spira, (unknown), Omid Hamid, (unknown), Karim A. Benhadji, Leila Alland, Xi Hu, Hong‐Ping Xiao, Xun Bao, (unknown), Yubao Gong, Xuesheng Liu	2
4	First-in-human phase I trial of the oral first-in-class ubiquitin specific peptidase 1 (USP1) inhibitor KSQ-4279 (KSQi), given as single agent (SA) and in combination with olaparib (OLA) or carboplatin (CARBO) in patients (pts) with advanced solid tumors, enriched for deleterious homologous recombination repair (HRR) mutations. 2024 ·Journal of Clinical Oncology ·Timothy A. Yap, Nehal J. Lakhani, Amita Patnaik, (unknown), Martin Gutierrez, Kathleen N. Moore, Benedito A. Carneiro, John L. Hays, Marilyn Huang, Patricia LoRusso, Andrew A. Wylie, (unknown), (unknown), Erica R. Tobin, Oliver Krieter, Daniela Schmid, Sophia M. Blake, Max Dieterich, Candice Jamois, Patricia M. Harris	9
5	Unlocking the Potential: Biomarkers of Response to Antibody-Drug Conjugates 2024 ·American Society of Clinical Oncology Educational Book ·Liliana Ascione, (unknown), (unknown), Dario Trapani, Patricia LoRusso, Emil Lou, Giuseppe Curigliano	24
6	Efficacy and Safety of the MDM2–p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series 2024 ·OncoTargets and Therapy ·Noboru Yamamoto, Anthony W. Tolcher, Navid Hafez, Iwona Ługowska, Rodryg Ramlau, Teresa Macarulla, (unknown), (unknown), Michael Teufel, Angela Märten, Patricia LoRusso	9
7	996MO Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced/metastatic solid tumors: Data from phase I dose escalation 2024 ·Annals of Oncology ·(unknown), Xiang Gao, Anthony J. Olszanski, (unknown), Gerald S. Falchook, (unknown), Philippe L. Bédard, Donald P. Orr, John P. Gibbs, Chang Li, Y-C. Huang, R. Gregory, R. Ramesh, (unknown), (unknown), Kaiyang Ding, Jeffrey J. Raizer, Patricia LoRusso	1
8	Efficacy and safety of brigimadlin (BI 907828), an MDM2–p53 antagonist, in patients (pts) with advanced biliary tract cancer: Data from two phase Ia/Ib dose-escalation/expansion trials. 2024 ·Journal of Clinical Oncology ·Teresa Macarulla, Noboru Yamamoto, Anthony W. Tolcher, Navid Hafez, Iwona Ługowska, Rodryg Ramlau, (unknown), (unknown), (unknown), (unknown), Patricia LoRusso	4
9	673P A phase I dose-escalation and expansion study evaluating the safety and efficacy of the MDM2–p53 antagonist brigimadlin (BI 907828) in patients (pts) with solid tumours 2023 ·Annals of Oncology ·(unknown), Patricia LoRusso, Noboru Yamamoto, Iwona Ługowska, Víctor Moreno, Ulrich M. Lauer, Chengping Hu, (unknown), (unknown), Mrinal M. Gounder	0
10	Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study 2022 ·Investigational New Drugs ·Patricia LoRusso, Mark J. Ratain, Toshihiko Doi, Drew Rasco, Maja J.A. de Jonge, Víctor Moreno, Benedito A. Carneiro, Lot A. Devriese, Adam M. Petrich, Dimple Modi, Susan E. Morgan-Lappe, Silpa Nuthalapati, Monica Motwani, Martin Dunbar, (unknown), Bruno C. Medeiros, Emiliano Calvo	19
11	Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors 2013 ·Clinical Cancer Research ·Patricia LoRusso, Pasi A. Jänne, Moacyr Oliveira, Naiyer A. Rizvi, Lisa Malburg, Vicki L. Keedy, Lorrin Yee, Catherine Copigneaux, Thore Hettmann, Chi‐Yuan Wu, Agnes Ang, Abdel‐Baset Halim, Robert A. Beckman, Darrin M. Beaupre, Jordan Berlin	74
12	A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine 2012 ·Journal of Clinical Oncology ·Ian E. Krop, Patricia LoRusso, Kathy D. Miller, Shanu Modi, Denise A. Yardley, Gladys Rodriguez, Ellie Guardino, Michael W. Lu, (unknown), Sandhya Girish, Lukas C. Amler, Eric P. Winer, Hope S. Rugo	274
13	Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors 2012 ·Investigational New Drugs ·Christina M. Annunziata, Elise C. Kohn, Patricia LoRusso, Nicole Houston, Robert L. Coleman, Manuela Buzoianu, Gabriel J. Robbie, Robert J. Lechleider	91
14	Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study 2011 ·Cancer Chemotherapy and Pharmacology ·(unknown), Scot C. Remick, Chris H. Takimoto, Ramesh K. Ramanathan, Angela M. Davies, Merrill J. Egorin, Anne Hamilton, Patricia LoRusso, Stephen Shibata, Heinz Josef Lenz, James W. Mier, John Sarantopoulos, Sridhar Mani, James R. Wright, S. Percy Ivy, Rachel Neuwirth, Lisa Von Moltke, Karthik Venkatakrishnan, Daniel Mulkerin	35
15	Erlotinib therapy for central nervous system hemangioblastomatosis associated with von Hippel-Lindau disease: a case report 2010 ·Journal of Neuro-Oncology ·Lisa R. Rogers, Patricia LoRusso, Paul I. Nadler, Ghaus M. Malik, Anthony F. Shields, William G. Kaelin	21
16	Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy 2008 ·Journal of Clinical Oncology ·Stephen Johnston, Maureen Trudeau, Bella Kaufman, Hamouda Boussen, (unknown), Patricia LoRusso, Donald P. Lombardi, Slim Ben Ahmed, Dennis L. Citrin, Michelle DeSilvio, Jennifer L. Harris, Ron E. Westlund, Vanessa Salazar, Tal Zaks, Neil L. Spector	152
17	A phase I study of the recombinant human IgG1 anti-IGF-IR monoclonal antibody (Mab) IMC-A12, administered on a weekly basis to patients with advanced solid tumors: Interim analysis 2007 ·Molecular Cancer Therapeutics ·(unknown), Patricia LoRusso, Michael A. Gordon, Evan Y. Yu, Samuel H. Whiting, Floyd E. Fox, Terry Katz, Eric K. Rowinsky, Hagop Youssoufian	9
18	Phase 1 clinical trials of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas 2007 ·Molecular Cancer Therapeutics ·Patricia LoRusso, Lorrin Yee, K. Papadopoulos, (unknown), (unknown), (unknown), Elisabeth I. Heath, G. Kenneth Lloyd, (unknown), Saskia Neuteboom, (unknown), G. Cropp, Matthew A. Spear, Monica Mita	1
19	A Phase II Study of Docetaxel, Doxorubicin, and Infusional 5-Fluorouracil in the Treatment of Patients With Locally Advanced Breast Cancer 2006 ·American Journal of Clinical Oncology ·(unknown), Priya Vishnubhotla, Laura Biernat, Lawrence E. Flaherty, Patricia LoRusso, Michael S. Simon, Deanna Stephens, (unknown), Judith Abrams, David L. Bouwman, Philip A. Philip	2
20	Chemotherapy for paranasal sinus carcinoma. A 10-year experience at Wayne state university 1988 ·Cancer ·Patricia LoRusso, Efstathios Tapazoglou, Julie A. Kish, John F. Ensley, (unknown), John Kelly, Muhyi Al‐Sarraf	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact